Core Viewpoint - DBV Technologies reported its financial results for the first quarter of 2025, highlighting significant cash usage in operations and ongoing clinical trials, while also announcing a financing plan to support its product development [1][5]. Financial Highlights - Cash and cash equivalents decreased to $13.0 million as of March 31, 2025, from $32.5 million at the end of 2024, reflecting a net decrease of $19.5 million, primarily due to $19.7 million used in operating activities [4][8]. - The company incurred operating losses and negative cash flows since inception, with no product revenue generated to date [6]. Cash Flow Analysis - The net cash flow used in operating activities was $19.7 million for Q1 2025, compared to $34.7 million for the same period in 2024, indicating an improvement in cash flow management [21]. - The company received gross proceeds of $125.5 million on April 7, 2025, as part of a financing plan of up to $306.9 million to support the Viaskin® Peanut Patch [5]. Operating Income and Expenses - Operating income for Q1 2025 was $0.8 million, down from $1.4 million in Q1 2024, attributed to a lower French Research Tax Credit due to more activities being conducted in North America [10][12]. - Total operating expenses decreased to $27.4 million in Q1 2025 from $30 million in Q1 2024, mainly due to reduced General & Administrative expenses [13][15]. Net Loss - The net loss for the first quarter of 2025 was $27.1 million, slightly improved from a net loss of $27.3 million in the same quarter of 2024 [16][17]. Financial Position - As of March 31, 2025, total assets were $50.6 million, down from $65.7 million at the end of 2024, with liabilities increasing to $47.7 million from $38.3 million [18]. Company Overview - DBV Technologies is focused on developing treatment options for food allergies using its proprietary Viaskin technology, which aims to provide non-invasive immunotherapy [22]. - The company is currently conducting clinical trials for its Viaskin Peanut product targeting peanut allergies in young children [22].